Serum erythropoietin level and mortality in kidney transplant recipients

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 12, 2011, Pages 2879-2886

  Molnar, Miklos Z ^a,b   Tabak, Adam G ^a   Alam, Ahsan ^c   Czira, Maria E ^a   Rudas, Anna ^a   Ujszaszi, Akos ^a   Beko, Gabriella ^a,e   Novak, Marta ^a,d   Kalantar Zadeh, Kamyar ^b,f,g   Kovesdy, Csaba P ^h,i   Mucsi, Istvan ^a,d  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Division of Nephrology   (United States)

ⁱ UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; ERYTHROPOIETIN; HEMOGLOBIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CAUSE OF DEATH; CHEMOLUMINESCENCE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MORTALITY; SOLID PHASE CHEMILUMINESCENT IMMUNOMETRIC ASSAY;

ADULT; AGED; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; KIDNEY TRANSPLANTATION; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS;

EID: 83155182221     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05590611     Document Type: Article

References (48)

1. Vanrenterghem Y: Anemia after kidney transplantation. Transplantation 87: 1265-1267, 2009
2. Lorenz M, Kletzmayr J, Perschl A, Furrer A, Horl WH, Sunder-Plassmann G: Anemia and iron deficiencies among longterm renal transplant recipients. J Am Soc Nephrol 13: 794-797, 2002
3. Molnar MZ, Novak M, Ambrus C, Kovacs A, Pap J, Remport A, Szeifert L, Mucsi I: Anemia in kidney transplanted patients. Clin Transplant 19: 825-833, 2005
4. Vanrenterghem Y, Ponticelli C, Morales JM, Abramowicz D, Baboolal K, Eklund B, Kliem V, Legendre C, Morais Sarmento AL, Vincenti F: Prevalence and management of anemia in renal transplant recipients: A European survey. Am J Transplant 3: 835-845, 2003
5. Molnar MZ, Czira M, Ambrus C, Szeifert L, Szentkiralyi A, Beko G, Rosivall L, Remport A, Novak M, Mucsi I: Anemia is associated with mortality in kidney-transplanted patients-A prospective cohort study. Am J Transplant 7: 818-824, 2007
6. Chhabra D, Grafals M, Skaro AI, Parker M, Gallon L: Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection. Clin J Am Soc Nephrol 3: 1168-1174, 2008
7. Heinze G, Kainz A, Horl WH, Oberbauer R: Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: Cohort study. BMJ 339: b4018, 2009
8. Djamali A, Becker YT, Simmons WD, Johnson CA, Premasathian N, Becker BN: Increasing hematocrit reduces early posttransplant cardiovascular risk in diabetic transplant recipients. Transplantation 76: 816-820, 2003
9. Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P: Electrocardiographic left ventricular hypertrophy in renal transplant recipients: Prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 14: 462-468, 2003
10. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J: Congestive heart failure in renal transplant recipients: Risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 13: 1084-1090, 2002
11. Messana JM, Chuang CC, Turenne M, Wheeler J, Turner J, Sleeman K, Tedeschi P, Hirth R: Association of quarterly average achieved hematocrit with mortality in dialysis patients: A time-dependent comorbidity-adjusted model. Am J Kidney Dis 53: 503-512, 2009
12. Rossert J, Gassmann-Mayer C, Frei D, McClellan W: Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant 22: 794-800, 2007
13. Lopez-Gomez JM, Portoles JM, Aljama P: Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int December: S75-S81, 2008
14. Kausz AT, Solid C, Pereira BJ, Collins AJ, St Peter W: Intractable anemia among hemodialysis patients: A sign of suboptimal management or a marker of disease? Am J Kidney Dis 45: 136-147, 2005
15. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74: 791-798, 2008
16. Kaysen GA, Muller HG, Ding J, Chertow GM: Challenging the validity of the EPO index. Am J Kidney Dis 47: 166, 2006
17. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ: Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44: 866-876, 2004
18. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA: Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 363: 1146-1155, 2010
19. Bradbury BD, Brookhart MA, Winkelmayer WC, Critchlow CW, Kilpatrick RD, Joffe MM, Feldman HI, Acquavella JF, Wang O, Rothman KJ: Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations. Am J Kidney Dis 54: 554-560, 2009
20. Streja E, Kovesdy CP, Greenland S, Kopple JD, McAllister CJ, Nissenson AR, Kalantar-Zadeh K: Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 52: 727-736, 2008
21. Wagner M, Alam A, Zimmermann J, Rauh K, Koljaja-Batzner A, Raff U, Wanner C, Schramm L: Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney disease. Clin J Am Soc Nephrol 6: 1573-1579, 2011
22. den Elzen WP, Willems JM, Westendorp RG, de Craen AJ, Blauw GJ, Ferrucci L, Assendelft WJ, Gussekloo J: Effect of erythropoietin levels on mortality in old age: The Leiden 85-plus Study. CMAJ 182: 1953-1958, 2010
23. Sinnamon KT, Courtney AE, Maxwell AP, McNamee PT, Savage G, Fogarty DG: Level of renal function and serum erythropoietin levels independently predict anaemia post-renal transplantation. Nephrol Dial Transplant 22: 1969-1973, 2007
24. Avkarogullari M, Bozkurt A, Akpinar O, Donmez Y, Demirtas M: The relation between serum erythropoietin level and severity of disease and mortality in patients with chronic heart failure. Acta Cardiol 63: 297-302, 2008
25. van der Meer P, Lok DJ, Januzzi JL, de la Porte PW, Lipsic E, van Wijngaarden J, Voors AA, van Gilst WH, van Veldhuisen DJ: Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J 29: 1510-1515, 2008
26. Kovesdy CP, Molnar MZ, Czira ME, Rudas A, Ujszaszi A, Rosivall L, Szathmari M, Covic A, Keszei A, Beko G, Lakatos P, Kosa J, Mucsi I: Associations between serum leptin level and bone turnover in kidney transplant recipients. Clin J Am Soc Nephrol 5: 2297-2304, 2010
27. Kovesdy CP, Czira ME, Rudas A, Ujszaszi A, Rosivall L, Novak M, Kalantar-Zadeh K, Molnar MZ, Mucsi I: Body mass index, waist circumference and mortality in kidney transplant recipients. Am J Transplant 10: 2644-2651, 2010
28. Molnar MZ, Czira ME, Rudas A, Ujszaszi A, Haromszeki B, Kosa JP, Lakatos P, Beko G, Sarvary E, Varga M, Fornadi K, Novak M, Rosivall L, Kiss I, Remport A, Goldsmith DJ, Kovesdy CP, Mucsi I: Association between the malnutritioninflammation score and post-transplant anaemia. Nephrol Dial Transplant 26: 2000-2006, 2011
29. Molnar MZ, Czira ME, Rudas A, Ujszaszi A, Lindner A, Fornadi K, Kiss I, Remport A, Novak M, Kennedy SH, Rosivall L, Kovesdy CP, Mucsi I: Association of the malnutrition-inflammation score with clinical outcomes in kidney transplant recipients. Am J Kidney Dis 58: 101-108, 2011
30. Molnar MZ, Keszei A, Czira ME, Rudas A, Ujszaszi A, Haromszeki B, Kosa JP, Lakatos P, Sarvary E, Beko G, Fornadi K, Kiss I, Remport A, Novak M, Kalantar-Zadeh K, Kovesdy CP, Mucsi I: Evaluation of the malnutrition-inflammation score in kidney transplant recipients. Am J Kidney Dis 56: 102-111, 2010
31. Jassal SV, Schaubel DE, Fenton SS: Baseline comorbidity in kidney transplant recipients: A comparison of comorbidity indices. Am J Kidney Dis 46: 136-142, 2005
32. Levey A, Greene T, Kusek J, Beck G, Group MS: A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 11: 155A, 2000
33. Belonje AM, Voors AA, van der Meer P, van Gilst WH, Jaarsma T, van Veldhuisen DJ: Endogenous erythropoietin and outcome in heart failure. Circulation 121: 245-251, 2010
34. Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayer WC: Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 303: 857-864, 2010
35. Sherwood JB, Carmichael LD, Goldwasser E: The heterogeneity of circulating human serum erythropoietin. Endocrinology 122: 1472-1477, 1988
36. Conlon PJ, Albers F, Butterly D, Schwab SJ: ACE inhibitors do not affect erythropoietin efficacy in haemodialysis patients. Nephrol Dial Transplant 9: 1358, 1994
37. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD: Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42: 761-773, 2003
38. Brines M, Cerami A: Erythropoietin-mediated tissue protection: Reducing collateral damage from the primary injury response. J Intern Med 264: 405-432, 2008
39. Smith KJ, Bleyer AJ, Little WC, Sane DC: The cardiovascular effects of erythropoietin. Cardiovasc Res 59: 538-548, 2003
40. George J, Patal S, Wexler D, Abashidze A, Shmilovich H, Barak T, Sheps D, Keren G: Circulating erythropoietin levels and prognosis in patients with congestive heart failure: Comparison with neurohormonal and inflammatory markers. Arch Intern Med 165: 1304-1309, 2005
41. Pasqualetti P, Casale R: Circadian rhythm of serum erythropoietin in healthy subjects. Riv Eur Sci Med Farmacol 18: 91-93, 1996
42. Roberts D, Smith DJ: Erythropoietin does not demonstrate circadian rhythm in healthy men. J Appl Physiol 80: 847-851, 1996
43. Khosroshahi HT, Asghari A, Estakhr R, Baiaz B, Ardalan MR, Shoja MM: Effects of azathioprine and mycophenolate mofetil-immunosuppressive regimens on the erythropoietic system of renal transplant recipients. Transplant Proc 38: 2077-2079, 2006
44. Al-Uzri A, Yorgin PD, Kling PJ: Anemia in children after transplantation: Etiology and the effect of immunosuppressive therapy on erythropoiesis. Pediatr Transplant 7: 253-264, 2003
45. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
46. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
47. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009
48. Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Rothman KJ, Fischer M, Mehta J, Winkelmayer WC: The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol 19: 1389-1395, 2008